Treatment of plantar fasciitis - comparison between hyaluronic acid and platelet rich plasma

Phase 2

Conditions: Health Condition 1: M722- Plantar fascial fibromatosis

Registration Number: CTRI/2022/04/041777

Lead Sponsor: Department of anaesthesiology and critical careJNMCH AMU ALIGARH

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Yet Recruiting

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

1.Age > 18 years and <60yrs.

2.Patients of plantar fascitis of atleast 6 weeks duration.

3.Patientâ??s pain refractory to primary conservative treatments (NRS >5).

4.Willingness to participate in the study and forgo any other concomitant treatment modality.

Exclusion Criteria

1.Unwillingness to participate in the study.

2.Arthrosis or arthritis of foot, old-healed tendoachilles rupture.

3.History of foot trauma or Surgery.

4.History of injection in the involved foot during preceding 6 months.

5.Patients with history of vascular insufficiency, neuropathic heel pain, on anti-platelet or anticoagulant therapy, and on aspirin containing NSAIDS.

6.Any foot and ankle deformity including pes planus or pes cavus.

7.Pregnant and Breastfeeding females.

8.Uncontrolled psychiatric disorder or major depression or other severe medical illness.

9.Local infection or ongoing septicaemia.

10.Patients with autoimmune disease, malignancy, uncontrolled diabetes mellitus, hyperlipidemia and patients with BMI >30.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1.To determine the degree of pain relief in patients of Plantar Fascitis using Numerical rating scale(NRS)Timepoint: baseline, 1st week, 2nd week, 4th week and 6th week.

Secondary Outcome Measures

Name	Time	Method
1.To evaluate the improvement in quality of life using foot health status questionnaire (FHSQ) at baseline and 6 weeks. <br/ ><br>2.Requirement of rescue analgesics on weekly basis. <br/ ><br>3.Any complication such as pain, bleeding, infection or any other complication occurring during and after the injection shall be noted. <br/ ><br>Timepoint: baseline, 1 week, 2 week, 4 week, 6 week